|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Foveal avascular zone area and parafoveal vessel density measurements in different stages of diabetic retinopathy by optical coherence tomography angiography显示文摘AIM:To investigate foveal avascular zone(FAZ) and parafoveal vessel densities(PRVD) by means of optical coherence tomography angiography(OCTA) in diabetic patients with or without diabetic retinopathy(DR) and to assess the reproducibility of FAZ and PRVD measurements.METHODS:Sixty diabetic patients(60 eyes) with different stage of DR(graded according to the International Clinical Severity Scale for DR) and 20 healthy subjects underwent FAZ area and PRVD measurements using OCTA by two experienced examiners.FAZ area in all patients was also assessed using fluorescein angiography(FA).RESULTS:In subject with proliferative DR and with moderate-severe non proliferative DR,FAZ area was significantly increased compared to healthy controls(P=0.025 and P=0.050 respectively measured with OCTA and P=0.025 and P=0.048 respectively measured with FA).OCTA showed significantly less inter-observer variability compared to FA.Concordance correlation coefficient(CCC) for FAZ area measurements was 0.829(95%CI:0.736-0.891) P<0.001 with FA and 1.000(95%CI:0.999-1.000) P<0.001 with OCTA.CCC was 0.834(95%CI:0.746-0.893) P<0.001 and 0.890(95%CI:0.828-0.930) P<0.001 for parafoveal superficial and deep vessel density measurements,respectively.CONCLUSION:OCTA shows progressive increase of FAZ area and reduction of PRVD in both superficial and deep plexus at increasing DR severity.FAZ area and PRVD measurements using OCTA are highly reproducible. | Rodolfo Mastropasqua Lisa Toto Alessandra Mastropasqua Raffaella Aloia Chiara De Nicola Peter A Mattei Guido Di Marzio Marta Di Nicola Luca Di Antonio | 2017 | International Journal of Ophthalmology(English edition)2017，10，10： | 26 |
| 2 | Then and now: The progress in hepatitis B treatment over the past 20 years显示文摘The ultimate goals of treating chronic hepatitis B(CHB)is prevention of hepatocellular carcinoma(HCC)and hepatic decompensation.Since the advent of effective antiviral drugs that appeared during the past two decades,considerable advances have been made not only in controlling hepatitis B virus(HBV)infection,but also in preventing and reducing the incidence of liver cirrhosis and HCC.Furthermore,several recent studies have suggested the possibility of reducing the incidence of recurrent or new HCC in patients even after they have developed HCC.Currently,six medications are available for HBV treatment including,interferon and five nucleoside/nucleotide analogues.In this review,we will examine the antiviral drugs and the progresses that have been made with antiviral treatments in the field of CHB. | Dina Halegoua-De Marzio Hie-Won Hann | 2014 | World Journal of Gastroenterology2014，20，2： | 19 |
| 3 | Laparoscopic fundoplication for gastroesophageal reflux disease显示文摘Gastroesophageal reflux disease(GERD) is a condition that develops when the reflux of gastric contents into the esophagus leads to troublesome symptoms and/or complications. Heartburn is the cardinal symptom, often associated with regurgitation. In patients with endoscopy-negative heartburn refractory to proton pump inhibitor(PPI) therapy and when the diagnosis of GERD is in question, direct reflux testing by impedance-pH monitoring is warranted. Laparoscopic fundoplication is the standard surgical treatment for GERD. It is highly effective in curing GERD with a 80% success rate at 20-year follow-up. The Nissen fundoplication, consisting of a total(360°) wrap, is the most commonly performed antireflux operation. To reduce postoperative dysphagia and gas bloating, partial fundoplications are also used, including the posterior(Toupet) fundoplication, and the anterior(Dor) fundoplication. Currently, there is consensus to advise laparoscopic fundoplication in PPI-responsive GERD only for those patients who develop untoward side-effects or complications from PPI therapy. PPI resistance is the real challenge in GERD. There is consensus that carefully selected GERD patients refractory to PPI therapy are eligible for laparoscopic fundoplication, provided that objective evidence of reflux as the cause of ongoing symptoms has been obtained. For this purpose, impedance-pH monitoring is regarded as the diagnostic gold standard. | Marzio Frazzoni Micaela Piccoli Rita Conigliaro Leonardo Frazzoni Gianluigi Melotti | 2014 | World Journal of Gastroenterology2014，20，39： | 10 |
| 4 | Cholangiocarcinoma and malignant bile duct obstruction: A review of last decades advances in therapeutic endoscopy显示文摘In the last decades many advances have been achieved in endoscopy, in the diagnosis and therapy of cholangiocarcinoma, however blood test, magnetic resonance imaging, computed tomography scan may fail to detect neoplastic disease at early stage, thus the diagnosis of cholangiocarcinoma is achieved usually at unresectable stage. In the last decades the role of endoscopy has moved from a diagnostic role to an invaluable therapeutic tool for patients affected by malignant bile duct obstruction. One of the major issues for cholangiocarcinoma is bile ducts occlusion, leading to jaundice, cholangitis and hepatic failure. Currently, endoscopy has a key role in the work up of cholangiocarcinoma, both in patients amenable to surgical intervention as well as in those unfit for surgery or not amenable to immediate surgical curative resection owing to locally advanced or advanced disease, with palliative intention. Endoscopy allows successful biliary drainage and stenting in more than 90% of patients with malignant bile duct obstruction, and allows rapid reduction of jaundice decreasing the risk of biliary sepsis. When biliary drainage and stenting cannot be achieved with endoscopy alone, endoscopic ultrasound-guided biliary drainage represents an effective alternative method affording successful biliary drainage in more than 80% of cases. The purpose of this review is to focus on the currently available endoscopic management options in patients with cholangiocarcinoma. | Helga Bertani Marzio Frazzoni Santi Mangiafico Angelo Caruso Mauro Manno Vincenzo Giorgio Mirante Flavia Pigò Carmelo Barbera Raffaele Manta Rita Conigliaro | 2015 | World Journal of Gastrointestinal Endoscopy2015，7，6： | 8 |
| 5 | CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis显示文摘AIM: To determine intra-hepatic blood flow and liver stiffness in patients with non-alcoholic fatty liver disease(NAFLD) and non-alcoholic steatohepatitis (NASH) using contrast-enhanced ultrasound and fibroscan.METHODS: This prospective study included 15 patients with NAFLD, 17 patients with NASH and 16 healthy controls.In each patient, real-time ultrasound was used to locate the portal vein (PV) and the right liver lobe, and 5 mL of SonoVue? was then injected intravenous in a peripheral vein of the left arm over a 4-s span. Digital recording was performed for 3 min thereafter. The recording was subsequently retrieved to identify an area of interest in the PV area and in the right liver parenchyma(LP) to assess the blood flow by processing the data using dedicated software (Qontrast?, Bracco, Italy).The following parameters were evaluated: percentage of maximal contrast activity (Peak%), time to peak (TTP, s), regional blood volume (RBV, cm3), regional blood flow (RBF, cm3/s) and mean transit time (MTT, s).At 24-48 h post-injection, liver stiffness was evaluated using Fibroscan and measured in kPa. The statistical evaluation was performed using Student’s t test.RESULTS: In the PV, the Peak%, RBV and RBF were significantly reduced in the NAFLD and NASH patientscompared with the controls (Peak%: NAFLD 26.3 ± 6.6,NASH 28.1 ± 7.3 vs controls 55.8 ± 9.9, P < 0.001;RBV: NAFLD 4202.3 ± 3519.7, NASH 3929.8 ± 1941.3vs controls 7473 ± 3281, P < 0.01; RBF: NAFLD 32.5± 10.8, NASH 32.7 ± 12.1 vs controls 73.1 ± 13.9, P< 0.001). The TTP in the PV was longer in both patient groups but reached statistical significance only in the NASH patients compared with the controls (NASH 79.5± 37.8 vs controls 43.2 ± 30, P < 0.01). In the LP,the Peak%, RBV and RBF were significantly reduced in the NAFLD and NASH patients compared with the controls (Peak%: NAFLD 43.2 ± 7.3, NASH 41.7 ± 7.7 vs controls 56.6 ± 6.3, P < 0.001; RBV: NAFLD 4851.5± 2009, NASH 5069.4 ± 2292.5 vs controls 6922.9 ±2461.5, P < 0.05; RBF: NAFLD 55.7 ± 10.1, NASH 54.5 ± 12.1 vs controls 75.9 ± 10.5, P < 0.001). The TTP was longer in both patient groups but did not reach statistical significance. The MTT in both the PV and LP in the NAFLD and NASH patients was not different from that in the controls. Liver stiffness was significantly increased relative to the controls only in the NASH patients(NASH: 6.4 ± 2.2 vs controls 4.6 ± 1.5, P < 0.05).CONCLUSION: Blood flow derangement within the liver present not only in NASH but also in NAFLD suggests that a vascular flow alteration precedes liver fibrosis development. | Sila Cocciolillo Giustino Parruti Leonardo Marzio | 2014 | World Journal of Hepatology2014，6，7： | 7 |
| 6 | The Gut Microbiota and Atherosclerosis:The State of the Art and Novel Perspectives显示文摘The human gut microbiota is composed of more than 100 trillion microbes.Most communities are dominated by species belonging to the phyla Bacteroidetes,Firmicutes,Actinobacteria,Proteobacteria,and Verrucomicrobia.Microfl ora-derived short-chain fatty acids play a pivotal role in the framework of insulin resistance,obesity,and metabolic syndrome.They are an important energy source and are involved in several pathways,with proatherogenic and antiatherogenic effects.The increased gut microbiota lipopolysaccharide levels(defi ned as“metabolic endotoxemia”)induce a state of low-grade infl ammation and are involved in atherosclerotic disease through Toll-like receptor 4.Another important infl ammatory trigger in gut microbiota–mediated atherosclerotic promotion is trimethylamine N-oxide.On the other hand,protocatechuic acid was found to promote cholesterol effl ux from macrophages,showing an antiatherogenic effect.Further studies to clarify specifi c gut composition involved in cardiometabolic syndrome and atherogenesis are needed for greater use of targeted approaches. | Giulio La Rosa Luigi Marzio Biasucci | 2016 | Cardiovascular Innovations and Applications2016，，B09： | 7 |
| 7 | Quadruple therapy with moxifloxacin and bismuth for first-line treatment ofHelicobacter pylori显示文摘AIM:To compare triple therapy vs quadruple therapy for 10 d as first-line treatment ofHelicobacter pylori(H.pylori) infection.METHODS:Consecutive H.pylori positive patients never treated in the past for this infection were randomly treated with triple therapy of pantoprazole(PAN) 20 mg bid,amoxicillin(AMO) 1 g bid and moxifloxacin(MOX) 400 mg bid for 10 d(PAM) or with quadruple therapy of PAN 20 mg bid,AMO 1 g bid,MOX 400 mg bid and bismuth subcitrate 240 mg bid for 10 d(PAMB).All patients were found positive at 13 C-Urea breath test(UBT) performed within ten days prior to the start of the study.A successful outcome was confirmed with an UBT performed 8 wk after the end of treatment.χ 2 analysis was used for statistical comparison.Per protocol(PP) and intention-to-treat(ITT) values were also calculated.RESULTS:Fifty-seven patients were enrolled in the PAM group and 50 in the PAMB group.One patient in each group did not return for further assessment.Eradication was higher in the PAMB group(negative:46 and positive:3) vs the PAM group(negative:44 and positive:12).The H.pylori eradication rate was statistically significantly higher in the PAMB group vs the PAM group,both with the PP and ITT analyses(PP:PAMB 93.8%,PAM 78.5%,P < 0.02;ITT:PAMB 92%,PAM 77.1 %,P <0.03).CONCLUSION:The addition of bismuth subcitrate can be considered a valuable adjuvant to triple therapy in those areas where H.pylori shows a high resistance to fluoroquinolones. | Antonio Francesco Ciccaglione Luigina Cellini Laurino Grossi Leonardo Marzio | 2012 | World Journal of Gastroenterology2012，18，32： | 5 |
| 8 | Vesical dysfunctions after radical hysterectomy for cervical cancer: a critical review显示文摘 | Marzio Angelo Zullo Natalina Manci Roberto Angioli Ludovico Muzii Pierluigi Benedetti Panici | 2003 | Critical Reviews in Oncology and Hematology2003，，3： | 4 |
| 9 | Pre-operative clinical and instrumental factors as antireflux surgery outcome predictors显示文摘Gastroesophageal reflux disease(GERD) is nowadays a highly prevalent, chronic condition, with 10% to 30% of Western populations affected by weekly symptoms. Many patients with mild reflux symptoms are treated adequately with lifestyle modifications, dietary changes, and low-dose proton pump inhibitors(PPIs). For those with refractory GERD poorly controlled with daily PPIs, numerous treatment options exist. Fundoplication is currently the most commonly performed antireflux operation for management of GERD. Outcomes described in current literature following laparoscopic fundoplication indicate that it is highly effective for treatment of GERD; early clinical studies demonstrate relief of symptoms in approximately 85%-90% of patients. However it is still unclear which factors, clinical or instrumental, are able to predict a good outcome after surgery. Virtually all demographic, esophagogastric junction anatomic conditions, as well as instrumental(such as presence of esophagitis at endoscopy, or motility patterns determined by esophageal high resolution manometry or reflux patterns determined by means of pH /impedance-pH monitoring) and clinical features(such as typical or atypical symptoms presence) of patients undergoing laparoscopic fundoplication for GERD can be factors associated with symptomatic relief. With this in mind, we sought to review studies that identified the factors that predict outcome after laparoscopic total fundoplication. | Salvatore Tolone Giorgia Gualtieri Edoardo Savarino Marzio Frazzoni Nicola de Bortoli Manuele Furnari Giuseppina Casalino Simona Parisi Vincenzo Savarino Ludovico Docimo | 2016 | World Journal of Gastrointestinal Surgery2016，8，11： | 3 |
| 10 | Reassessing the environmental Kuznets curve for CO 2 emissions: A robustness exercise显示文摘 | Marzio Galeotti Alessandro Lanza Francesco Pauli | 2005 | Ecological Economics2005，，1： | 3 |
| 11 | Histologic analysis of endometriomas: what the surgeon needs to know显示文摘 | Ludovico Muzii Antonella Bianchi Filippo Bellati Emanuela Cristi Milena Pernice Marzio A. Zullo Roberto Angioli Pierluigi Benedetti Panici | 2007 | Fertility and Sterility2007，，2： | 2 |
| 12 | Rockets and feathers revisited:an international comparison on European gasoline markets显示文摘 | Marzio Galeotti Alessandro Lanza Matteo Manera | 2003 | Energy Economics2003，25，： | 1 |
| 13 | Endogenous Induced Techni- cal Change and the Costs of Kyoto 显示文摘 | Paolo Buonanno Carlo Carraro Marzio Galeotti | 2003 | Resource and Energy Economics2003，，25： | 1 |
| 14 | Desperatly seeking Environmental Kuznets 显示文摘 | MARZIO GALEOTTI ALESSANDRO LANZA | 2005 | Environmental Modelling&software2005，，20： | 1 |
| 15 | Determination of sulfonamide antibiotics by gas chromatography coupled withatomic emission detection 显示文摘 | CHIAVARINO B CRESTONI M E MARZIO A D | 1998 | Journal of Chromatography B1998，706，： | 1 |
| 16 | At home and abroad: An empirical analysis of innovation and diffusion in energy technologies显示文摘 | Elena Verdolini Marzio Galeotti | 2010 | Journal of Environmental Economics and Management2010，，2： | 1 |
| 17 | On the forces transmitted to a vibrating cylinder by a blowing fluid显示文摘 | Giorgio Diana Marzio Falco | 1971 | Meccanica1971，，1： | 1 |
| 18 | Quanti- tative developments in the cognitive reliability and error analysis method (CREAM) for the assessment of human performance显示文摘 | Marseguerra Marzio Zio Enrico Librizzi Massimo | 2006 | Annals of Nuclear Energy2006，33，10： | 1 |
| 19 | Economic Growth,International Competitiveness and Environmental Protection:R&D and Innovation Strategies with the Warm Model显示文摘 | Carlo Carraroh Marzio Galeotti | 1997 | Energy Economics1997，，19： | 1 |
| 20 | Novel pH - sensitive non - ionic surfactant vesicles : Comparison between Tween 21 and Tween 20 显示文摘 | MARZIO D L MARIANECCI C PETRONE M | 2011 | Colloids and Surfaces B : Biointerfaces2011，82，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员